Sartorius Stedim Biotech Reports Q1 2025 Results with Strong Growth

Sartorius Stedim Biotech, a prominent partner in the biopharmaceutical industry, has published its unaudited results for Q1 2025. The company reported a 10.4% increase in sales revenue to 745 million euros, with a book-to-bill ratio above 1. All global regions contributed to this growth, including a notable 13.8% rise in the Americas.

The first quarter showcased a significant demand for consumables, leading to an underlying EBITDA of 229 million euros and an EBITDA margin of 30.8%. Net profit climbed to 85 million euros, a 51.8% increase compared to 2024. Key financial indicators remain robust, with net operating cash flow jumping 116% to 120 million euros.

For 2025, Sartorius Stedim Biotech forecasts a sales growth of around 7% and a consistent EBITDA margin of 30-31%. Investments in global infrastructure were lower than planned, and the capex to sales ratio stood at 8.8% for the quarter.